Micafungin: A promising inhibitor of UBE2M in cancer cell growth suppression

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Neddylation is a critical protein modification process implicated in cancer progression.
• Overactive neddylation fuels oncogenic activities, making its enzymes, like UBE2M, key therapeutic targets.
• Targeting UBE2M is vital for cancer treatment due to its role in DNA damage, apoptosis, and proliferation, but druggable pockets are scarce.

Purpose of the Study:

• To identify novel inhibitors of UBE2M, a key enzyme in the neddylation pathway.
• To explore the potential of Micafungin, an antifungal agent, as an anti-cancer therapeutic targeting UBE2M.
• To elucidate the anti-cancer mechanism of Micafungin through its interaction with UBE2M.

Main Methods:

• Biochemical assays to assess Micafungin's effect on neddylation and UBE2M stability.
• Cellular experiments in gastric cancer cells to evaluate drug-target interaction and downstream effects.
• Analysis of UBE2M interaction, neddylation inhibition, CRLs substrate accumulation, cell survival, migration, and DNA damage.

Main Results:

• Micafungin was identified as a neddylation inhibitor that specifically targets UBE2M.
• Biochemical studies confirmed Micafungin obstructs neddylation and stabilizes UBE2M.
• Cellular studies demonstrated Micafungin's interaction with UBE2M, leading to reduced cell survival and migration, and induced DNA damage in gastric cancer cells.

Conclusions:

• Micafungin exhibits a novel anti-cancer mechanism by inhibiting UBE2M-mediated neddylation.
• This study reveals Micafungin as a potential therapeutic agent for gastric cancer.
• The findings pave the way for developing a new class of UBE2M-targeting neddylation inhibitors for cancer therapy.